Amyloidosis: Accurate Subtyping Using Novel Diagnostic Methodology [Featured Topic]

At least 25 different proteins have been shown to cause amyloidosis and the underlying pathogenesis of each subtype of amyloidosis is unique. The treatment approach for each subtype of amyloidosis may be radically different. Mayo Clinic has developed a novel diagnostic methodology that can subtype amyloidosis in routine biopsy specimens with high accuracy. The method combines specific sampling of the amyloid plaques by laser microdissection and the analytical power of tandem mass spectrometry-based proteomic analysis.

View Full Article



Brent Westra is a Marketing Segment Manager at Mayo Clinic Laboratories. He leads marketing strategies for product management and specialty testing along with new media innovations. Brent has worked at Mayo Clinic since 2011.

Leave a Reply

Your email address will not be published. Required fields are marked *